Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

Rhea-AI Summary

Vir Biotechnology announced that Phil Pang, M.D., Ph.D., their executive vice president and chief medical officer, will present at the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference on October 18, 2022, at 10:30 a.m. PT / 1:30 p.m. ET. A live webcast of the presentation can be accessed on the Vir website and will be available for 30 days.

Vir focuses on immunology and has a pipeline targeting serious infectious diseases such as COVID-19 and hepatitis B.

SAN FRANCISCO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., executive vice president, chief medical officer and interim head of research, is scheduled to present at the H. C. Wainwright 3^rd Annual Hepatitis B Virus (HBV) Conference on Tuesday, October 18, at 10:30 a.m. PT / 1:30 p.m. ET.

A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

FAQ

When is Phil Pang's presentation at the H. C. Wainwright Conference for VIR?

Phil Pang's presentation is scheduled for October 18, 2022, at 10:30 a.m. PT / 1:30 p.m. ET.

Where can I watch the webcast of the presentation by VIR?

The webcast can be accessed under Events & Presentations on the Vir website.

What is the focus of Vir Biotechnology as a company?

Vir Biotechnology focuses on combining immunologic insights with technologies to treat serious infectious diseases.

What diseases is Vir Biotechnology currently targeting?

Vir's development pipeline targets COVID-19, hepatitis B and D viruses, influenza A, and HIV.

How long will the webcast of Phil Pang's presentation be available?

The webcast will be archived on the Vir website for 30 days after the event.